Recombinant Pertussis Vaccine

Pertussis, commonly known as “whooping cough”, is a very contagious respiratory illness caused by a type of bacteria called Bordetella pertussis. Pertussis vaccination is recommended during childhood as part of the Expanded Program of Immunization (EPI). The recent rise in pertussis cases urges for the replacement of current acellular Pertussis vaccines using a chemically-inactivated pertussis toxin by vaccines containing a genetically-detoxified pertussis toxin.

The recombinant DNA technology eliminates the need for chemical inactivation of the vaccine components and produces more native and active ingredients. Thus a much lower dose of active ingredient is needed in the final vaccine when compared to conventional acellular Pertussis vaccines. This prompted BioNet to develop an innovative Recombinant Pertussis vaccine.

BioNet has recently filed a patent application for its Recombinant Pertussis Vaccine which is currently evaluated in clinical trials.